Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2019

Open Access 01-12-2019 | Review

Technologies for circulating tumor cell separation from whole blood

Authors: Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho, András Telekes

Published in: Journal of Hematology & Oncology | Issue 1/2019

Login to get access

Abstract

The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using technological innovations. One of the key research fields involves the separation and detection of circulating tumor cells (CTC) because of their suggested important role in early cancer diagnosis and prognosis, namely, providing easy access by a liquid biopsy from blood to identify metastatic cells before clinically detectable metastasis occurs and to study the molecular and genetic profile of these metastatic cells. Provided the opportunity to further progress the development of technology for treating cancer, several CTC technologies have been proposed in recent years by various research groups and companies. Despite their potential role in cancer healthcare, CTC methods are currently mainly used for research purposes, and only a few methods have been accepted for clinical application because of the difficulties caused by CTC heterogeneity, CTC separation from the blood, and a lack of thorough clinical validation. Therefore, the standardization and clinical application of various developed CTC technologies remain important subsequent necessary steps. Because of their suggested future clinical benefits, we focus on describing technologies using whole blood samples without any pretreatment and discuss their advantages, use, and significance. Technologies using whole blood samples utilize size-based, immunoaffinity-based, and density-based methods or combinations of these methods as well as positive and negative enrichment during separation. Although current CTC technologies have not been truly implemented yet, they possess high potential as future clinical diagnostic techniques for the individualized therapy of patients with cancer. Thus, a detailed discussion of the clinical suitability of these new advanced technologies could help prepare clinicians for the future and can be a foundation for technologies that would be used to eliminate CTCs in vivo.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790–801.PubMedCrossRef
3.
Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 2010;10:283.PubMedPubMedCentralCrossRef
4.
McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009;27:5650–9.PubMedCrossRef
5.
Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54:1770–9.PubMedCrossRef
6.
Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89–95.PubMedCrossRef
7.
Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. Obstet Gynecol Surv. 2015;70:612–4.CrossRef
8.
Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–56.PubMedPubMedCentralCrossRef
9.
10.
Ashkenazi R, Gentry SN, Jackson TL. Pathways to tumorigenesis--modeling mutation acquisition in stem cells and their progeny. Neoplasia. 2008;10:1170–82.PubMedPubMedCentralCrossRef
11.
Ruddon RW, Holland F. What makes a cancer cell a cancer cell? In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al., editors. Holland-Frei cancer medicine. 6th ed. New York: Academic Press; 2003. p. 1–29.
12.
13.
14.
15.
16.
Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152–62.PubMedCrossRef
17.
18.
Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010;16:5233–43.PubMedCrossRef
19.
Paget S. The distribution of secondary growths in cancer of the breast. Lancet Oncol. 1889;133:571–3.CrossRef
20.
Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMed
21.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.PubMedCrossRef
22.
Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93:1638–43.PubMedCrossRef
23.
Ming Y, Li Y, Xing H, Luo M, Li Z, Chen J, et al. Circulating tumor cells: from theory to nanotechnology-based detection. Front Pharmacol. 2017;8:1–11.CrossRef
24.
Esmaeilsabzali H, Beischlag TV, Cox ME, Parameswaran AM, Park EJ. Detection and isolation of circulating tumor cells: principles and methods. Biotechnol Adv. 2013;31:1063–84.PubMedCrossRef
25.
Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6:339–51.PubMedCrossRef
26.
27.
Bunger S, Zimmermann M, Habermann JK. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials. Cancer Metastasis Rev. 2015;34:527–45.PubMedCrossRef
28.
Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351–65.PubMedPubMedCentralCrossRef
29.
Jin C, McFaul SM, Duffy SP, Deng X, Tavassoli P, Black PC, et al. Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. Lab Chip. 2014;14:32–44.PubMedCrossRef
30.
31.
Hosokawa M, Yoshikawa T, Negishi R, Yoshino T, Koh Y, Kenmotsu H, et al. Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. Anal Chem. 2013;85:5692–8.PubMedCrossRef
32.
Yeh Y-T, Harouaka RA, Zheng S-Y. Evaluating a novel dimensional reduction approach for mechanical fractionation of cells using a tandem flexible micro spring array (tFMSA). Lab Chip. 2017;17:691–701.PubMedCrossRef
33.
Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, et al. Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep. 2014;4:7392.PubMedPubMedCentralCrossRef
34.
Kim TH, Lim M, Park J, Oh JM, Kim H, Jeong H, et al. FAST: Size-selective, clog-free isolation of rare cancer cells from whole blood at a liquid-liquid interface. Anal Chem. 2017;89:1155–62.PubMedCrossRef
35.
Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014;9:694–710.PubMedPubMedCentralCrossRef
36.
Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, et al. Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol. 2010;2010:861341.PubMedPubMedCentralCrossRef
37.
Mikolajczyk SD, Millar LS, Tsinberg P, Coutts S, Zomorrodi M, Pham T, et al. Detection of epcam-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011;2011:252361.CrossRef
38.
Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011;1:580–6.PubMedPubMedCentralCrossRef
39.
Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M, et al. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget. 2014;5:7486–97.PubMedPubMedCentralCrossRef
40.
Hyun KA, Jung HI. Advances and critical concerns with the microfluidic enrichments of circulating tumor cells. Lab Chip. 2014;14:45–56.PubMedCrossRef
41.
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012;7:e33788.PubMedPubMedCentralCrossRef
42.
Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9:e111597.PubMedPubMedCentralCrossRef
43.
Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73:2965–75.PubMedCrossRef
44.
Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14:147–56.PubMedCrossRef
45.
Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E, et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol. 2015;17:539–46.PubMedPubMedCentralCrossRef
46.
Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009;118:523–30.PubMedCrossRef
47.
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.PubMedCrossRef
48.
Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol. 2016;43:464–75.PubMedPubMedCentralCrossRef
49.
Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920–8.PubMedCrossRef
50.
Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014;14:456.PubMedPubMedCentralCrossRef
51.
Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11:231–8.PubMedCrossRef
52.
Xiong K, Wei W, Jin Y, Wang S, Zhao D, Wang S, et al. Biomimetic immuno-magnetosomes for high-performance enrichment of circulating tumor cells. Adv Mater. 2016;28:7929–35.PubMedCrossRef
53.
Lu N-N, Xie M, Wang J, Lv S-W, Yi J-S, Dong W-G, et al. Biotin-triggered decomposable immunomagnetic beads for capture and release of circulating tumor cells. ACS Appl Mater Interfaces. 2015;7:8817–26.PubMedCrossRef
54.
Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Gottert J, et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc. 2008;130:8633–41.PubMedPubMedCentralCrossRef
55.
Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis. 2009;30:3289–300.PubMedPubMedCentralCrossRef
56.
Dharmasiri U, Njoroge SK, Witek MA, Adebiyi MG, Kamande JW, Hupert ML, et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem. 2011;83:2301–9.PubMedPubMedCentralCrossRef
57.
Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–9.PubMedPubMedCentralCrossRef
58.
Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 2010;10:27–9.PubMedCrossRef
59.
Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol. 2013;8:735–41.PubMedPubMedCentralCrossRef
60.
Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, et al. Tunable thermal-sensitive polymer–graphene oxide composite for efficient capture and release of viable circulating tumor cells. Adv Mater. 2016;28:4891–7.PubMedPubMedCentralCrossRef
61.
Teotia AK, Sami H, Kumar A. Thermo-responsive polymers: structure and design of smart materials. In: Zhang Z, editor. Switchable and responsive surfaces and materials for biomedical applications. Oxford: Woodhead Publishing; 2015. p. 3–43.CrossRef
62.
Wang S, Liu K, Liu J, Yu ZT, Xu X, Zhao L, et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl. 2011;50:3084–8.PubMedPubMedCentralCrossRef
63.
Park MH, Reategui E, Li W, Tessier SN, Wong KH, Jensen AE, et al. Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic chip. J Am Chem Soc. 2017;139:2741–9.PubMedPubMedCentralCrossRef
64.
65.
Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, et al. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013;12:2132–43.PubMedPubMedCentralCrossRef
66.
Ma Y, Hao S, Wang S, Zhao Y, Lim B, Lei M, et al. A combinatory strategy for detection of live ctcs using microfiltration and a new telomerase-selective adenovirus. Mol Cancer Ther. 2015;14:835–43.PubMedPubMedCentralCrossRef
67.
Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014;60:323–33.PubMedCrossRef
68.
Huang T, Jia CP, Jun Y, Sun WJ, Wang WT, Zhang HL, et al. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip. Biosens Bioelectron. 2014;51:213–8.PubMedCrossRef
69.
Tan SJ, Yobas L, Lee GYH, Ong CN, Lim CT. Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices. 2009;11:883–92.PubMedCrossRef
70.
Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016;138:2894–904.PubMedPubMedCentralCrossRef
71.
72.
Hosokawa M, Hayata T, Fukuda Y, Arakaki A, Yoshino T, Tanaka T, et al. Size-selective microcavity array for rapid and efficient detection of circulating tumor cells. Anal Chem. 2010;82:6629–35.PubMedCrossRef
73.
Yagi S, Koh Y, Akamatsu H, Kanai K, Hayata A, Tokudome N, et al. Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. PLoS One. 2017;12:e0179744.PubMedPubMedCentralCrossRef
74.
Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002;49:150–8.PubMedCrossRef
75.
Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015;15:360.PubMedPubMedCentralCrossRef
76.
Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, et al. Monolithic chip for high-throughput blood cell depletion to sort rare circulating tumor cells. Sci Rep. 2017;7:10936.PubMedPubMedCentralCrossRef
77.
Sajay BN, Chang CP, Ahmad H, Khuntontong P, Wong CC, Wang Z, et al. Microfluidic platform for negative enrichment of circulating tumor cells. Biomed Microdevices. 2014;16:537–48.PubMedCrossRef
78.
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95:4589–94.PubMedPubMedCentralCrossRef
79.
Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 2009;102:521–34.PubMedPubMedCentralCrossRef
80.
Lara O, Tong X, Zborowski M, Chalmers JJ. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol. 2004;32:891–904.PubMedCrossRef
81.
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–44.PubMedCrossRef
82.
Pantel K, Deneve E, Nocca D, Coffy A, Vendrell JP, Maudelonde T, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58:936–40.PubMedCrossRef
83.
Cauley CE, Pitman MB, Zhou J, Perkins J, Kuleman B, Liss AS, et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings. J Am Coll Surg. 2015;221:699–707.PubMedPubMedCentralCrossRef
84.
Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14:R133.PubMedPubMedCentralCrossRef
85.
Crisan D, Ruark DS, Decker DA, Drevon AM, Dicarlo RG. Detection of circulating epithelial cells after surgery for benign breast disease. Mol Diagn. 2000;5:33–8.PubMed
86.
Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61:259–66.PubMedCrossRef
87.
Sheng W, Ogunwobi OO, Chen T, Zhang J, George TJ, Liu C, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip. 2014;14:89–98.PubMedCrossRef
88.
Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009;106:3970–5.PubMedPubMedCentralCrossRef
89.
90.
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012;11:2526–34.PubMedPubMedCentralCrossRef
91.
Pluim D, Devriese LA, Beijnen JH, Schellens JH. Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. Cytometry A. 2012;81:664–71.PubMedCrossRef
92.
Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339:971–5.PubMedPubMedCentralCrossRef
93.
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–77.PubMedPubMedCentralCrossRef
94.
Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010;107:18392–7.PubMedPubMedCentralCrossRef
95.
Peters CE, Maestre-Battle D, Woodside SM, Thomas TE, Eaves AC. Unbiased enrichment of circulating tumor cells directly from whole blood abstract. In: Proceedings of the 107th annual meeting of the american association for cancer research. New Orleans: AACR; 2016. p. Abstract nr 511.
96.
Harouaka RA, Nisic M, Zheng SY. Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013;18:455–68.PubMedCrossRef
97.
Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, et al. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. 2016;7:3662–76.PubMedCrossRef
98.
99.
Coumans FA, van Dalum G, Beck M, Terstappen LW. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One. 2013;8:e61770.PubMedPubMedCentralCrossRef
100.
Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5:179ra47.PubMedPubMedCentralCrossRef
101.
Apel P. Track etching technique in membrane technology. Radiat Meas. 2001;34:559–66.CrossRef
102.
Tan SJ, Lakshmi RL, Chen P, Lim WT, Yobas L, Lim CT. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron. 2010;26:1701–5.PubMedCrossRef
103.
Miller MC, Robinson PS, Wagner C, O'Shannessy DJ. The parsortix cell separation system-a versatile liquid biopsy platform. Cytometry A. 2018;93:1234–9.PubMedCrossRefPubMedCentral
104.
Magbanua M, Jesus M, Park JW. Circulating tumor cells methods in molecular biology. New York: Humana Press; 2017.CrossRef
105.
Cho H, Kim J, Song H, Sohn KY, Jeon M, Han KH. Microfluidic technologies for circulating tumor cell isolation. Analyst. 2018;143:2936–70.PubMedCrossRef
106.
Chudziak J, Burt DJ, Mohan S, Rothwell DG, Mesquita B, Antonello J, et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst. 2016;141:669–78.PubMedCrossRef
107.
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One. 2015;10:e0138032.PubMedPubMedCentralCrossRef
108.
Yoshino T, Kanbara H, Negishi R, Takai K, Matsunaga T, Tanaka T. Towards single-cell genome analysis of circulating tumor cells based on microcavity array. In: Yoshino T, Kanbara H, Negishi R, Takai K, Matsunaga T, Tanaka T, editors. World automation congress. Rio Grande, Puerto Rico: IEEE; 2016. p. 1–11.
109.
Negishi R, Hosokawa M, Nakamura S, Kanbara H, Kanetomo M, Kikuhara Y, et al. Development of the automated circulating tumor cell recovery system with microcavity array. Biosens Bioelectron. 2015;67:438–42.PubMedCrossRef
110.
Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, et al. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One. 2013;8:e67466.PubMedPubMedCentralCrossRef
111.
Balic M, Dandachi N, Hofmann G, Samonigg H, Loibner H, Obwaller A, et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom. 2005;68:25–30.PubMedCrossRef
112.
113.
Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010;10:666.PubMedPubMedCentralCrossRef
114.
Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017;114:1123–8.PubMedPubMedCentralCrossRef
115.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.PubMedCrossRef
116.
Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.PubMedCrossRef
117.
Zahn H, Steif A, Laks E, Eirew P, VanInsberghe M, Shah SP, et al. Scalable whole-genome single-cell library preparation without preamplification. Nat Methods. 2017;14:167–73.PubMedCrossRef
118.
Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. Nat Rev Genet. 2016;17:175–88.PubMedCrossRef
119.
Vitak SA, Torkenczy KA, Rosenkrantz JL, Fields AJ, Christiansen L, Wong MH, et al. Sequencing thousands of single-cell genomes with combinatorial indexing. Nat Methods. 2017;14:302–8.PubMedPubMedCentralCrossRef
120.
Zilionis R, Nainys J, Veres A, Savova V, Zemmour D, Klein AM, et al. Single-cell barcoding and sequencing using droplet microfluidics. Nat Protoc. 2017;12:44–73.PubMedCrossRef
121.
Kim YR, Yoo JK, Jeong CW, Choi JW. Selective killing of circulating tumor cells prevents metastasis and extends survival. J Hemat Oncol. 2018;11:114.CrossRef
Metadata
Title
Technologies for circulating tumor cell separation from whole blood
Authors
Petra Bankó
Sun Young Lee
Viola Nagygyörgy
Miklós Zrínyi
Chang Hoon Chae
Dong Hyu Cho
András Telekes
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2019
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-019-0735-4

Other articles of this Issue 1/2019

Journal of Hematology & Oncology 1/2019 Go to the issue

Research

CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis

Review

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Research

Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis

Research

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Review

Molecular pathogenic pathways in extranodal NK/T cell lymphoma

Review

Emerging trends in immunotherapy for pediatric sarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits